Searched for
BIOPHARMA INNOVATIONS
Indian pharma's risk aversion holding back innovation: Kiran Mazumdar-ShawBiocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push f...- Our central mission must be patient-centric innovation: JP NaddaJ P Nadda urges industry to take discoveries ‘from bench to bedside’ as the FICCI–Lilly Bharat Life Sciences Award backs its inaugural coho...
- Indian companies must invest in R&D, move from generics to innovation-led industry: Pharma leadersIndian pharmaceutical leaders emphasize the need for investment in innovation to transition from generics to innovative products. They high...
- Where Does China Fit in Your Company’s Innovation Strategy?For decades, multinationals treated China primarily as either a vast growth market or a rising competitive threat. But as growth slows, com...
- Agonisingly slow clinical trial is stopping Indian pharma become global innovator from supplierIndia's regulatory hurdles slow down early-stage drug trials significantly. This complexity causes Indian companies to conduct crucial firs...
- Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Biocon's Shaw says Budget boosts India’s health and innovation agendaThe Union Budget is making a significant investment in India's health and innovation. Biopharma has been identified as a key strategic sect...
- Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitionsIndia's biopharmaceutical sector receives a significant boost with the Union Budget's ₹10,000 crore Biopharma SHAKTI programme. This initia...
- Budget 2026: Sitharaman proposes Rs 10,000-crore Biopharma Shakti scheme to boost biopharma manufacturingThe proposed fund aims to position India as a global biopharma manufacturing hub
- India emerging as favourable destination to conduct global clinical trials: ReportThe joint report by the USA India Chamber of Commerce & PwC India titled, “Clinical Trial opportunities in India” which will be released at...
- Infinion Biopharma files draft papers with Sebi to mop-up funds through IPOProceeds from the IPO will be used towards investment in Mobius Biomedical Inc, acquisition of licenses for product development of skincare...
- Top government officials, leaders from industry, academicians to take part in India-US Biopharma and Healthcare SummitNITI Aayog CEO Amitabh Kant, Pfizer CEO Dr Alberta Bourla, National Institutes of Health (NIH) Director Dr Francis Collins and Food and Dru...
- Pharma sector needs global collaboration: Industry leaders, government officialsAhead of the 14th edition of the annual BioPharma and Healthcare Summit, that bring stakeholders from India and the United States on one pl...
- India's health and biopharma sector deserve more attentionIndia's health and innovative and biopharma sector deserves better attention from the government to help realise its full potential
- Biocon to invest 10% of biopharma revenues on R&D next fiscalThe Bengaluru-based company has spent Rs 47 crore on R&D in the third quarter of this fiscal, an increase of 124 per cent over the correspo...
- Policy, infrastructure main hurdles in Indian pharma R&D: ReportThe McKinsey report commissioned by the US-India Chamber of Commerce would be released at the US-India BioPharma and Healthcare Summit 2013...
- India needs to step up to be a biopharma major, says Boston Consulting Group"India offers several advantages in R&D, but it's behind," said Bart Janssens, a BCG partner and coauthor of the report.
- India can become innovation hub for bio-pharma: BCG reportEmerging markets will drive 70% of growth in the pharma industry and India will require supportive policies to leverage the BioPharma.
Load More
